(^50) BIOEVENT BIOSPECTRUM | SEPTEMBER 2018 | http://www.biospectrumindia.com
U
BM India recently hosted the 5th edition
of PharmaLytica 2018 in Hyderabad at the
HITEX Exhibition Centre, with BioSpectrum
serving as the conference partner. The two day event
was inaugurated by Dr Preeti Meena, Director, Drugs
Control Administration, Hyderabad along with Uday
Bhaskar Reddy, Director General, Pharmaceuticals
Export Promotion Council (PHARMEXCIL), Dr Appaji
PV, Director General Emeritus, PHARMEXCIL, Avinash
Talwar, Director & Head, Global Sourcing (Strategic &
Plant) Dr. Reddy’s Laboratories Ltd, Dr R B Smarta,
Managing Director, Interlink Marketing Consultancy,
Yogesh Mudras, Managing Director, UBM India and
Rahul Deshpande, Group Director, UBM India amidst a
gathering of industry experts and government officials.
PharmaLytica event over the years has been
providing a platform to the pharmaceutical community
to procure the current industry trends, innovations
and conduct business with Analytical, Laboratory,
Machinery, Packaging and other allied Industries.
The expo is well supported by associations, including
Pharmexcil, Confederation of Indian Pharmaceutical
Industry (CiPi) and Indian Drug Manufacturers’
Association (IDMA).
At the inaugural session, Uday Bhaskar Reddy,
DG, PHARMEXCIL said, “In FY 2017-18, Indian
Pharma exports grew to $17.26 billion. One of the key
development to notice is, despite 8 per cent negative
growth witnessed in the US market, we still grew
positive by 2.92 per cent. There are potential markets to
explore like China, South Africa and Commonwealth ofIndependent States (CIS) markets and even if negative
growth continues in the US market, the Indian pharma
companies should be confident and focus on growth and
explore opportunities in the potential markets.”
Over the two days, experts from organisations
such as Dr. Reddy’s Laboratory, Novartis Healthcare,
Deloitte, Pfizer Healthcare, USP India, Aztec India,
Apex Lab deliberated over the various trends and issues
related to quality assurance technologies, maintenance
of quality culture and regulatory compliance standards
within the Indian pharmaceutical sector.
“The availability of good quality drugs is of extreme
importance. Today, the Indian population is suffering
from a large number diseases such as hypertension,
diabetes etc. We need to make sure that our drugs are
free from impurities and toxicity. Good manufacturing
set ups are required in the pharmaceutical production
facilities to ensure the correct quality of the products.
We are accountable for using appropriate machinery,
equipment and other inputs in order to ensure quality
production. We also need to maintain data integrity
which is a very critical issue of deviation. Wherever
required, global standards should be implemented even
if it comes in return with high pricing”, said Dr Appaji
PV, DG Emeritus, PHARMEXCIL, during the first
session of the two-day event. PharmaLytica witnessed
a participation from over 150 exhibitors from across
the country-Kirloskar, Standard Group of Companies,
Borosil Glass Works, Bry-Air Asia, Rotomark
Innovations, Control Print, Gandhi Automation,
Leistung Engineering among many others.PharmaLytica 2018
Indian pharma should explore
opportunities in potential markets
L-R- Rahul Deshpande, Group
Director, UBM India; Yogesh
Mudras, Managing Director, UBM
India; Uday Bhaskar Reddy,
Director General, Pharmaceuticals
Export Promotion Council
(PHARMEXCIL); Dr P V
Appaji, Director General
Emeritus, Pharmaceuticals
Export Promotion Council
(PHARMEXCIL); Avinash
Talwar, Director & Head, Global
Sourcing (Strategic & Plant)
Dr. Reddy’s Laboratories Ltd;
Dr.R B Smarta, MD, Interlink
Marketing Consultancy, Milind
Kokje, Chief Editor, BioSpectrum
at the inauguration ceremony of
the 5th Edition of PharmaLytica
at the Hitex Exhibition Centre,
Hyderabad, India.